186 related articles for article (PubMed ID: 24510012)
1. A combination treatment with DNA methyltransferase inhibitors and suramin decreases invasiveness of breast cancer cells.
Borges S; Döppler HR; Storz P
Breast Cancer Res Treat; 2014 Feb; 144(1):79-91. PubMed ID: 24510012
[TBL] [Abstract][Full Text] [Related]
2. Pharmacologic reversion of epigenetic silencing of the PRKD1 promoter blocks breast tumor cell invasion and metastasis.
Borges S; Döppler H; Perez EA; Andorfer CA; Sun Z; Anastasiadis PZ; Thompson E; Geiger XJ; Storz P
Breast Cancer Res; 2013 Aug; 15(2):R66. PubMed ID: 23971832
[TBL] [Abstract][Full Text] [Related]
3. Protein kinase D1 regulates matrix metalloproteinase expression and inhibits breast cancer cell invasion.
Eiseler T; Döppler H; Yan IK; Goodison S; Storz P
Breast Cancer Res; 2009; 11(1):R13. PubMed ID: 19243594
[TBL] [Abstract][Full Text] [Related]
4. Modulation of protein expression levels and DNA methylation status of breast cancer metastasis genes by anthracycline-based chemotherapy and the demethylating agent decitabine.
Ari F; Napieralski R; Ulukaya E; Dere E; Colling C; Honert K; Krüger A; Kiechle M; Schmitt M
Cell Biochem Funct; 2011 Dec; 29(8):651-9. PubMed ID: 21887697
[TBL] [Abstract][Full Text] [Related]
5. Decitabine potentiates efficacy of doxorubicin in a preclinical trastuzumab-resistant HER2-positive breast cancer models.
Buocikova V; Longhin EM; Pilalis E; Mastrokalou C; Miklikova S; Cihova M; Poturnayova A; Mackova K; Babelova A; Trnkova L; El Yamani N; Zheng C; Rios-Mondragon I; Labudova M; Csaderova L; Kuracinova KM; Makovicky P; Kucerova L; Matuskova M; Cimpan MR; Dusinska M; Babal P; Chatziioannou A; Gabelova A; Rundén-Pran E; Smolkova B
Biomed Pharmacother; 2022 Mar; 147():112662. PubMed ID: 35091237
[TBL] [Abstract][Full Text] [Related]
6. Combined inhibition of DNA methylation and histone acetylation enhances gene re-expression and drug sensitivity in vivo.
Steele N; Finn P; Brown R; Plumb JA
Br J Cancer; 2009 Mar; 100(5):758-63. PubMed ID: 19259094
[TBL] [Abstract][Full Text] [Related]
7. ER alpha negative breast cancer cells restore response to endocrine therapy by combination treatment with both HDAC inhibitor and DNMT inhibitor.
Fan J; Yin WJ; Lu JS; Wang L; Wu J; Wu FY; Di GH; Shen ZZ; Shao ZM
J Cancer Res Clin Oncol; 2008 Aug; 134(8):883-90. PubMed ID: 18264725
[TBL] [Abstract][Full Text] [Related]
8. Demethylating agent 5-aza-2-deoxycytidine enhances susceptibility of breast cancer cells to anticancer agents.
Mirza S; Sharma G; Pandya P; Ralhan R
Mol Cell Biochem; 2010 Sep; 342(1-2):101-9. PubMed ID: 20455010
[TBL] [Abstract][Full Text] [Related]
9. Epigenetic reactivation of estrogen receptor-α (ERα) by genistein enhances hormonal therapy sensitivity in ERα-negative breast cancer.
Li Y; Meeran SM; Patel SN; Chen H; Hardy TM; Tollefsbol TO
Mol Cancer; 2013 Feb; 12():9. PubMed ID: 23379261
[TBL] [Abstract][Full Text] [Related]
10. S-adenosylmethionine in combination with decitabine shows enhanced anti-cancer effects in repressing breast cancer growth and metastasis.
Mahmood N; Arakelian A; Cheishvili D; Szyf M; Rabbani SA
J Cell Mol Med; 2020 Sep; 24(18):10322-10337. PubMed ID: 32720467
[TBL] [Abstract][Full Text] [Related]
11. Combination therapy with epigenetic-targeted and chemotherapeutic drugs delivered by nanoparticles to enhance the chemotherapy response and overcome resistance by breast cancer stem cells.
Li SY; Sun R; Wang HX; Shen S; Liu Y; Du XJ; Zhu YH; Jun W
J Control Release; 2015 May; 205():7-14. PubMed ID: 25445694
[TBL] [Abstract][Full Text] [Related]
12. A rapid screening system evaluates novel inhibitors of DNA methylation and suggests F-box proteins as potential therapeutic targets for high-risk neuroblastoma.
Penter L; Maier B; Frede U; Hackner B; Carell T; Hagemeier C; Truss M
Target Oncol; 2015 Dec; 10(4):523-33. PubMed ID: 25559288
[TBL] [Abstract][Full Text] [Related]
13. Altered DNA methylation is associated with docetaxel resistance in human breast cancer cells.
Kastl L; Brown I; Schofield AC
Int J Oncol; 2010 May; 36(5):1235-41. PubMed ID: 20372798
[TBL] [Abstract][Full Text] [Related]
14. [Arsenic trioxide restores ERα expression in ERα-negative human breast cancer cells and its treatment efficacy in combination with tamoxifen in xenografts in nude mice].
Zhang WJ; Xu DF; Fan QX; Wu XA; Wang F; Wang R; Wang LX
Zhonghua Zhong Liu Za Zhi; 2012 Sep; 34(9):645-51. PubMed ID: 23159075
[TBL] [Abstract][Full Text] [Related]
15. Reexpression of tumor suppressor, sFRP1, leads to antitumor synergy of combined HDAC and methyltransferase inhibitors in chemoresistant cancers.
Cooper SJ; von Roemeling CA; Kang KH; Marlow LA; Grebe SK; Menefee ME; Tun HW; Colon-Otero G; Perez EA; Copland JA
Mol Cancer Ther; 2012 Oct; 11(10):2105-15. PubMed ID: 22826467
[TBL] [Abstract][Full Text] [Related]
16. Highly synergistic effect of sequential treatment with epigenetic and anticancer drugs to overcome drug resistance in breast cancer cells is mediated via activation of p21 gene expression leading to G2/M cycle arrest.
Vijayaraghavalu S; Dermawan JK; Cheriyath V; Labhasetwar V
Mol Pharm; 2013 Jan; 10(1):337-52. PubMed ID: 23215027
[TBL] [Abstract][Full Text] [Related]
17. Hydroxycarbamide in combination with azacitidine or decitabine is antagonistic on DNA methylation inhibition.
Choi SH; Byun HM; Kwan JM; Issa JP; Yang AS
Br J Haematol; 2007 Sep; 138(5):616-23. PubMed ID: 17686055
[TBL] [Abstract][Full Text] [Related]
18. ETAR antagonist ZD4054 exhibits additive effects with aromatase inhibitors and fulvestrant in breast cancer therapy, and improves in vivo efficacy of anastrozole.
Smollich M; Götte M; Fischgräbe J; Macedo LF; Brodie A; Chen S; Radke I; Kiesel L; Wülfing P
Breast Cancer Res Treat; 2010 Sep; 123(2):345-57. PubMed ID: 19943105
[TBL] [Abstract][Full Text] [Related]
19. Effects of a novel DNA methyltransferase inhibitor zebularine on human breast cancer cells.
Billam M; Sobolewski MD; Davidson NE
Breast Cancer Res Treat; 2010 Apr; 120(3):581-92. PubMed ID: 19459041
[TBL] [Abstract][Full Text] [Related]
20. The role of the polyamine catabolic enzymes SSAT and SMO in the synergistic effects of standard chemotherapeutic agents with a polyamine analogue in human breast cancer cell lines.
Pledgie-Tracy A; Billam M; Hacker A; Sobolewski MD; Woster PM; Zhang Z; Casero RA; Davidson NE
Cancer Chemother Pharmacol; 2010 May; 65(6):1067-81. PubMed ID: 19727732
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
